Do you need a license to sell peptides?

There is no standalone "peptide license" a business applies for. What your company actually needs depends on how the material is classified, how it is labeled and marketed, who you sell it to, and which state's rules attach to your entity and your buyer — and those determinations belong to your attorney and, where a regulated practice is involved, your state board. Most businesses reselling research-use-only compounds begin from ordinary commercial requirements — a registered entity, a sales tax or resale permit, any local business license — and then work through whether any additional distribution or professional framework applies to them. This article describes the questions worth resolving and the documentation worth demanding from a supplier. It is informational, not legal advice.

The word 'license' is doing too much work

When an operator asks about licensing, they are usually asking several unrelated questions at once, and each one is answered by a different body.

The first is corporate: is your entity formed and registered where it does business, and does the jurisdiction require a general business license? The second is tax: are you collecting and remitting correctly, and do you hold a resale certificate — the document most wholesale suppliers require before they will open an account, because it substantiates a sale for resale rather than a retail transaction. The third is distribution: depending on how a product is classified, some states operate wholesale distributor or device distributor registration schemes, and whether any of them reaches a research-use-only material is a classification question, not a marketing question. The fourth is professional: if the buyer holds a license — a medical, nursing, pharmacy or veterinary credential — that license carries its own scope-of-practice and advertising obligations that exist independently of anything a supplier sells or says.

None of those four is "the peptide license," because that credential does not exist as a single item. Your obligations are assembled, not issued.

What actually determines which rules reach your business

Four variables do most of the work, and they interact.

Classification. How a material is treated in law generally turns on what it is and what it is offered for, and intended use is typically evidenced by how the seller describes it. That is why two businesses shipping the same vial can sit in very different positions. Whether a given compound in your catalog falls inside or outside any particular regulatory framework is a question to put to counsel in writing, with your actual product pages and labels attached.

Labeling. The label is not decoration. Research-use-only labeling that is contradicted by the website, the ad copy or a sales call is weak labeling.

Buyer type. Selling business-to-business to entities that have their own compliance posture is a materially different transaction from selling to the general public. Ask counsel what buyer verification, if any, your model should include.

Geography. State frameworks vary, and they change. What a peer operator does in another state tells you nothing reliable about your own obligations — confirm with your state board and your attorney rather than with a forum thread.

Research-use-only is a discipline, not a disclaimer

The single most common failure in this category is treating research-use-only as a footnote rather than an operating rule. A disclaimer at the bottom of a page does not neutralize a dosing chart at the top of it.

Holding the line means the same story appears everywhere: on the label, on the product page, in the invoice, in the email autoresponder, in what a sales rep says on the phone, and in the ad creative. It means no administration guidance, no dosing tables, no protocols, no outcome claims about people, and no imagery that implies personal use. It also means not assembling compounds and injection supplies into anything that reads as a ready-to-use kit — which is why Real Peptides does not bundle bacteriostatic water or syringes with compounds. The bundle itself communicates intent, regardless of what the disclaimer says.

Catalog composition is part of the same discipline. Some categories draw far more regulatory attention than others, and the right move is to ask counsel which categories your specific business should and should not stock before you build a storefront around them — not after. For the same reason, a reputable wholesale supplier will decline to carry or supply certain compounds at all. If a supplier is willing to sell you anything you ask for, that is information about the supplier.

Questions worth putting to counsel and your state board

Bring these in writing, with your real product list and real page copy attached. Vague questions get vague answers, and vague answers are worthless if anyone ever asks you to justify your position.

• How is each compound in my intended catalog classified, and does that classification pull me into any registration scheme in the states where I operate and ship?
• Does my professional license — or the license of anyone on my team — constrain what I may sell, advertise, or say about these materials?
• What buyer verification, if any, should my sales process include, and what records of it should I retain?
• What labeling text should appear on the product, on the invoice, and on the web page, and who approves changes to it?
• What advertising claims are off-limits for my business, and who reviews copy before it goes live?
• What supplier documentation do I need to retain, in what form, and for how long?
• If a regulator or a payment processor asks me to substantiate my compliance posture tomorrow, what file do I hand them?

That last question is the useful one. Most operators discover the gaps in their program the moment they try to assemble that file.

The documentation chain you should be able to produce

Licensing questions and sourcing questions converge on the same place: paperwork that exists before anyone asks for it.

At minimum, you want a certificate of analysis tied to the specific lot you received — not a generic document, not a COA from a neighbouring batch, not a screenshot with the date cropped. The COA should name the analytical method used for identity and purity rather than asserting a number without one. High-performance liquid chromatography is the standard method for purity in this category, and a document that reports a purity figure without naming how it was measured is an assertion, not a result.

Beyond purity, ask what else is actually tested. Purity alone says nothing about endotoxin, heavy metals, residual solvents, moisture content, or microbial contamination. A supplier that runs a defined multi-point panel on every batch and publishes the outcome is operating differently from one that runs a single test and calls it lab verified.

Then ask the question that separates most suppliers: can you see the results without asking? A COA you have to request, pay for, or negotiate is a COA that can be curated before it reaches you.

Supplier practices that should slow a purchase down

You do not need to name and shame anyone to recognize patterns worth avoiding.

Hidden pricing is the first. If wholesale tiers, minimums and terms only appear after a sales call, the pricing is a negotiation rather than a program, and you cannot model your costs against it. Second is testing that cannot be verified — "third-party tested" with no lab named, no method stated, and no document you can inspect. Third is charging for documentation, or supplying COAs only on request, which inverts the relationship: the evidence should come with the product. Fourth, and most serious, is a supplier who volunteers guidance on human use, offers protocols, or markets research compounds with outcome language. That supplier is handing you their risk along with their inventory, and their marketing becomes part of the record around your purchase.

Unclear country of fulfillment belongs on the list too. Long, opaque supply chains make lot traceability harder precisely when you need it most.

What Real Peptides does differently

Real Peptides operates its Wholesale Partner Program around evidence that a buyer can check independently rather than claims a buyer has to accept.

Compounds are tested to 99%+ HPLC purity, and every batch runs through a seven-panel test rather than a single purity check. The resulting certificates of analysis are publicly verifiable — a prospective partner can inspect lab results before opening an account, not after committing to an order, and without paying for the document. Orders are fulfilled from within the United States, with typical delivery in five to seven days, which keeps lot traceability short and inventory planning realistic. Pricing tiers and program terms are stated rather than negotiated behind a call.

Everything in the catalog, across the popular research compounds and the specialist categories alike, is supplied for laboratory and research use only. Real Peptides does not supply, and does not represent that it supplies, GLP-1 class compounds such as semaglutide, tirzepatide or retatrutide, and does not pair compounds with injection supplies. Where published research is relevant to a compound, the honest framing is that studies indicate certain mechanisms of interest — never that a compound treats, heals, or produces an outcome in a person.

Becoming a partner runs through a three-step wholesale application: submit your business details, complete verification, and receive your tier pricing and account access.

Where that leaves a qualified buyer

If you have your entity and tax registrations in order, you have asked counsel the classification and marketing questions specific to your catalog, and you can hold a research-use-only line consistently across everything your business publishes, the remaining variable is your supplier — and that one you can evaluate on documentation alone, today, before you spend anything.

You can review program tiers and requirements on the wholesale peptides program page, and qualified businesses can apply for a wholesale account to begin verification.